Copyright
©The Author(s) 2021.
World J Hepatol. Nov 27, 2021; 13(11): 1791-1801
Published online Nov 27, 2021. doi: 10.4254/wjh.v13.i11.1791
Published online Nov 27, 2021. doi: 10.4254/wjh.v13.i11.1791
Characteristic | n (%) or means ± SD |
Gender M/F | 59/47 (56/44) |
Age (yr) | 51 ± 13 |
BMI (kg/m2) | 25.7 ± 4.7 |
PASP (mmHg) | 25.4 ± 8.0 |
Cirrhosis etiology | |
Virus | 36 (33.9) |
Alcohol | 32 (30.2) |
NASH | 8 (7.5) |
Others | 30 (28.4) |
Child-Pugh class n | 7.1 ± 1.8 |
A | 23 (21.7) |
B | 70 (66) |
C | 13 (12.3) |
MELD | 11.1 ± 3.1 |
Previous history of liver related decompensation | 76 (73.8) |
Hypertension | 19 (17.9) |
Diabetes | 26 (24.5) |
Tobacco smoking | 12 (11.4) |
Beta-blocker use | 32 (30.2) |
Hepatic decompensation on the day of the test | |
Ascites | 34 (32.1) |
(Grade 1, 2, and 3) | (11.3, 17, 5) |
Peripheral edema | 13 (12.3) |
Hepatic encephalopathy | 13 (12.3) |
(Grade 1, 2, 3, and 4) | (10.4, 1.9, 0, 0) |
Hepatocellular carcinoma | 5 (4.7) |
Patient on the liver transplantation waiting list | 35 (33) |
Baseline laboratory1 | |
Hemoglobin (mg/dL) | 13.1 ± 1.9 |
Hematocrit (%) | 39.3 ± 5.4 |
Albumin (g/dL)Bilirubin (mg/dL)INR | 3.5 ± 0.62.0 ± 1.51.2 ± 0.2 |
Creatinine (mg/dL) | 0.8 ± 0.3 |
Na (mmol/L) | 137.8 ± 2.1 |
K (mmol/L) | 4.1 ± 0.5 |
Mg (mg/dL) | 1.8 ± 0.2 |
Ca (mmol/L) | 1.2 ± 0.1 |
Variable | 6MWD (m) | P | 6MWD (%) | P |
(t-test when applicable) | (t-test when applicable) | |||
Mean 6MWD (m) | 515 ± 138 | |||
Mean 6MWD (%) | 0.91 ± 2.3 | |||
6MWD according to Child classes | ||||
A | 570 ± 144 | 0.97 ± 0.22 | ||
B | 504 ± 137 | 0.88 ± 0.21 | ||
C | 471 ± 115 | 0.82 ± 0.25 | ||
6MWD according to | ||||
Liver decompensation | ||||
Ascites (w vs wo) | 473 ± 20 vs 535 ± 17 | 0.03 | 0.86 ± 0.22 vs 0.95 ± 0.21 | 0.028 |
Hepatic encephalopathy (w vs wo) | 435 ± 34 vs 525 ± 14 | 0.04 | 0.87 ± 0.25 vs 0.91 ± 0.21 | 0.87 |
History of previous hepatic decompensation (w vs wo) | 496 ± 141 vs 571 ± 115 | 0.02 | 0.86 ± 0.22 vs 1.02 ± 0.17 | 0.004 |
Hospital admission during follow-up (w vs wo) | 444 ± 172 vs 531 ± 125 | 0.01 | 0.77 ± 0.25 vs 0.92 ± 0.20 | 0.004 |
Survival (died vs survived) | 423 ± 122 vs 526 ± 137 | 0.02 | 0.72 ± 0.21 vs 0.93 ± 0.21 |
Hospital Admission | Mortality | ||||||||||||
Predictors | Univariate | Multivariate | Univariate | Multivariate | |||||||||
b | p | OR | b | p | OR | b | p | OR | b | p | OR | ||
Child score | 0.74 | < 0.01 | 2.1 | 0.72 | < 0.01 | 2.05 | 1.01 | < 0.01 | 2.75 | 1.03 | < 0.01 | 2.8 | |
6MWD | -0.005 | < 0.01 | 0.99 | -0.005 | 0.24 | 0.99 | -0.007 | 0.01 | 0.99 | -0.007 | 0.04 | 0.99 | |
%6MWD | -0.04 | 0.01 | 0.96 | -0.03 | 0.03 | 0.96 | -0.05 | 0.02 | 0.95 | -0.05 | 0.03 | 0.95 | |
6MWD ≤ 444 m | -1.395 | 0.007 | 0.3 | -1.462 | 0.01 | 0.2 | - | - | - | - | - | - | |
6MWD ≤ 387 m | - | - | - | - | - | - | 1.659 | 0.004 | 5.25 | -1.17 | 0.2 | 0.31 |
- Citation: Pimentel CFMG, Amaral ACC, Gonzalez AM, Lai M, Mota DO, Ferraz MLG, Junior WM, Kondo M. Six-minute walking test performance is associated with survival in cirrhotic patients. World J Hepatol 2021; 13(11): 1791-1801
- URL: https://www.wjgnet.com/1948-5182/full/v13/i11/1791.htm
- DOI: https://dx.doi.org/10.4254/wjh.v13.i11.1791